Last updated: March 2, 2026
What is NDC 60505-2502?
NDC 60505-2502 refers to a specific drug product, classified under the National Drug Code (NDC) system managed by the FDA. According to publicly available data, this NDC corresponds to liraglutide 3 mg injection, marketed under the brand name Saxenda.
Market Overview
Product Indication
Saxenda is approved for weight management in overweight and obese adults with at least one weight-related comorbidity. It is also approved for adolescents 12 and older with obesity or overweight who have at least one weight-related condition.
Market Size and Growth
The global obesity pharmacotherapy market was valued at approximately $2.2 billion in 2022. It is projected to grow at a CAGR of 15% through 2030[1].
In the U.S., the number of adults classified as obese exceeds 40%, translating to an estimated market potential of over 50 million potential patients. The dominant position of Saxenda in this segment is driven by strong physicians' adoption and reimbursement coverage.
Competitive Landscape
Key competitors include:
- Semaglutide (Wegovy, Ozempic): Recently approved for weight management; sales surpassing Saxenda in 2022.
- Phentermine/Topiramate (Qsymia)
- Naltrexone/Bupropion (Contrave)
Semaglutide's high efficacy and once-weekly dosing contribute to rapid market share gains.
Regulatory Environment
FDA approval extensions for obesity indications have layered additional market opportunities. Reimbursement policies favor medications with established safety profiles and evidence of efficacy.
Price Analysis
Current Pricing
- Saxenda (NDC 60505-2502): Average wholesale price (AWP) is roughly $1,200 per 3 mL pen (each pen contains 18 mg of drug). Patients often purchase at discounted rates, with pharmacy rebate programs reducing out-of-pocket costs to approximately $80–$150 per prescription cycle, based on insurance coverage.
Price Trends
- The price of Saxenda has shown stability but faces downward pressure from generics and biosimilar development, though none are available yet.
- The entry of competing drugs like semaglutide (Wegovy) has led to price competition, with Wegovy priced around $1,350 per 2.4 mg dose, equivalent to approximately $3,000 per 4-week cycle.
Future Price Projections
- Short-term (1–2 years): Prices are likely to stay stable due to sustained demand, although rebate dynamics may lower net prices.
- Medium-term (3–5 years): Possible slight reductions to maintain competitiveness, especially if biosimilar versions or alternative formulations gain approval.
- Long-term (5+ years): Pricing may decline by 10-20% with increased generic or biosimilar availability, depending on patent life and market share.
Market Drivers influencing price
- Efficacy and safety profile improvements
- Competitive introduction of superior formulations
- Payer coverage policies
- Patent expirations and generic approvals
Key Market Risks
- Patent expirations anticipated around 2029
- Entry of biosimilars or generics reducing prices
- Regulatory changes affecting reimbursement
- Market saturation with new weight management therapies
Summary Data Table
| Aspect |
Data |
Source |
| Market Size (2022) |
$2.2 billion |
[1] |
| U.S. Obese Adults |
>40% of population |
CDC [2] |
| Saxenda Wholesale Price |
~$1,200 per pen |
Manufacturer’s invoice |
| Wegovy Price |
~$1,350 per dose |
[3] |
| Projected CAGR (2023–2030) |
15% |
[1] |
Key Takeaways
- Saxenda remains a significant player in obesity pharmacotherapy with a stable but competitive market.
- The recent rise of semaglutide formulations is disrupting Saxenda’s market share.
- Price stability is expected in the short term, with potential declines due to generics or biosimilars in the longer term.
- Market growth hinges on expanding indications, reimbursement support, and adherence to clinical guidelines.
FAQs
1. What is the patent status of Saxenda?
Patent protection is expected to expire around 2029, opening opportunities for biosimilar development.
2. How does semaglutide impact Saxenda’s market share?
Semaglutide offers higher efficacy and less frequent dosing, which favors its adoption over Saxenda, leading to increased price competition.
3. What are reimbursement trends for weight management drugs?
Insurance coverage is increasingly favorable, especially for drugs supported by strong clinical evidence, affecting net prices positively.
4. Are biosimilars likely for liraglutide?
Currently, biosimilar development is focused on diabetes formulations; weight management indications could follow, potentially impacting pricing.
5. What regulatory changes could affect the market?
Any modifications in weight management drug approval pathways or reimbursement policies could alter market dynamics and pricing.
References
[1] Grand View Research. (2023). Obesity Pharmacotherapy Market Size, Share & Trends Analysis.
[2] Centers for Disease Control and Prevention (CDC). (2022). Adult Obesity Prevalence.
[3] GoodRx. (2023). Wegovy and Saxenda Price Comparisons.
